Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage.
Flibotte
J J
JJ
Stroke Service and Neurology Clinical Trials Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
Hagan
N
N
O'Donnell
J
J
Greenberg
S M
SM
Rosand
J
J
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D001057:Apolipoproteins E / Q000235:genetics; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005838:Genotype; D006406:Hematoma / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000401:mortality / Q000473:pathology; D017052:Hospital Mortality; D006801:Humans; D006943:Hyperglycemia / Q000150:complications; D006973:Hypertension / Q000150:complications; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects; D011446:Prospective Studies; D011859:Radiography; D012306:Risk; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects*
D000925:Anticoagulants; D001057:Apolipoproteins E; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin